Development and Characterization of Recombinant Ovine Factor VIII

被引：0
|
作者：
Zakas, Philip M. [1 ]
Gangadharan, Bagirath [2 ,3 ]
Almeida-Porada, Graca [4 ]
Porada, Christopher D. [4 ]
Spencer, H. Trent [2 ,3 ]
Doering, Christopher B. [2 ,3 ]
机构：
[1] Emory Univ, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Aflac Canc Ctr, Atlanta, GA USA
[3] Emory Univ, Sch Med, Blood Disorders Serv, Atlanta, GA USA
[4] Inst Regenerat Med, Winston Salem, NC USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：538 / 538
页数：1
相关论文
共 50 条
  • [31] Structural and functional characterization of B-domain deleted recombinant factor VIII
    Sandberg, H
    Almstedt, A
    Brandt, J
    Castro, VM
    Gray, E
    Holmquist, L
    Lewin, M
    Oswaldsson, U
    Mikaelsson, M
    Jankowski, MA
    Bond, M
    Scoble, HA
    SEMINARS IN HEMATOLOGY, 2001, 38 (02) : 4 - 12
  • [32] THROMBIN ACTIVATION OF RECOMBINANT FACTOR-VIII (RECOMBINATE) - CHARACTERIZATION OF RESULTANT POLYPEPTIDES
    ANDRADE, J
    APFELZWEIG, R
    AMPHLETT, G
    KORTE, J
    LIU, SL
    BESMAN, MJ
    TRANSFUSION, 1992, 32 (05) : 484 - 484
  • [33] Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII
    Barrow, R. T.
    Lollar, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (10) : 2223 - 2229
  • [34] Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of Recombinant Factor VIII replacement therapy
    Giles, AR
    Rivard, GE
    Teitel, J
    Walker, I
    TRANSFUSION SCIENCE, 1998, 19 (02): : 139 - 148
  • [35] Modified factor VIII and factor IX recombinant products
    Santagostino, Elena
    Mancuso, Maria Elisa
    HEMASPHERE, 2018, 2 : 185 - 187
  • [36] Recombinant factor VIII products and hemophilia A: Efficacy, safety, and inhibitor development - Preface
    Mammen, EF
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (03): : 239 - 240
  • [37] Development and validation of a virus removal filtration step for recombinant Factor VIII (ReFacto).
    Orlando, S
    Petrone, J
    Kelley, B
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U251 - U251
  • [38] INHIBITOR DEVELOPMENT IN RATS IMMUNIZED WITH PURIFIED HUMAN RECOMBINANT FACTOR-VIII
    JARVIS, MA
    LEVIN, LG
    HARRISON, JA
    DEPIANTO, DJ
    BROWN, JE
    SUZUKI, CM
    JOLLY, K
    REISNER, HM
    POWELL, JS
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1028 - 1028
  • [39] Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors
    Abou-Ismail, Mouhamed Yazan
    Vuyyala, Sowjanya
    Prunty, Jeremy
    Schmaier, Alvin H.
    Nayak, Lalitha
    HAEMOPHILIA, 2020, 26 (04) : 601 - 606
  • [40] Measurement of factor VIII activity of B-domain deleted recombinant factor VIII
    Mikaelsson, M
    Oswaldsson, U
    Jankowski, MA
    SEMINARS IN HEMATOLOGY, 2001, 38 (02) : 13 - 23
12345